Vaccine to prevent EBV-related cancer in transplant patients
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a vaccine (OSU-2131) that may help prevent cancers caused by the Epstein-Barr virus in people waiting for an organ transplant. The vaccine is designed to train your immune system to fight the virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a specific immune system marker called HLA-B*08:01
- You can have had the Epstein-Barr virus before or not
- You must test negative for HIV, hepatitis B, and hepatitis C
- Your blood counts and liver/kidney tests must be mostly normal
- You must not be taking antiviral medications or certain immune-suppressing drugs
- For the second part of the study, you must have end-stage kidney disease and be on dialysis waiting for a kidney transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving special immune cells (called cytotoxic T lymphocytes) can fight viruses like CMV, adenovirus, EBV, or BK virus that are not responding to usual treatments. It is for people aged 0 to 29 with weakened immune systems due to inherited conditions or previous transplants.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
This trial tests if an experimental drug can prevent a common virus (EBV) from causing problems in people who receive a kidney from an EBV-positive donor but have never been exposed to EBV themselves. It aims to reduce the risk of transplant-related complications.
This trial tests a new treatment using specially prepared immune cells (called T cells) that fight the Epstein-Barr virus (EBV). It is for people who have EBV-related conditions, especially after a stem cell or organ transplant, and aims to help control the disease.
This trial tests a vaccine that may help prevent diseases caused by the Epstein-Barr virus (EBV) after a stem cell transplant. It could lower the risk of infections and related complications.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
Hear when a new Chronic Kidney Disease Stage 4 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.